Inovalon Receives a Sell from Morgan Stanley

By George MacDonald

According to The Fly, morgan Stanley analyst Zachary Sopcak reiterated a Sell rating on Inovalon (NASDAQ: INOV) today and set a price target of $16. The company’s shares opened today at $17.20, close to its 52-week low of $15.12.

According to, Sopcak is a 2-star analyst with an average return of 0.6% and a 40.0% success rate. Sopcak covers the Technology sector, focusing on stocks such as Medidata Solutions, Castlight Health, and Quality Systems.

Inovalon has an analyst consensus of Hold, with a price target consensus of $26


Based on Inovalon`s latest earnings report from March 31, the company posted quarterly revenue of $102.7M and quarterly net profit of $2.37M. In comparison, last year the company earned revenue of $93.63M and had a net profit of $13.76M.

Like Morgan Stanley`s latest rating, based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Keith Dunleavy, a the CEO & Chairman of the Board of INOV bought 30,000 shares for a total of $500,440.

Inovalon Holdings, Inc. operates as a technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and improvement in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Its powerful platform drives high-value impact, improving quality and economics for health plans, hospitals, physicians, patients, pharmaceutical companies, and researchers. Inovalon Holdings was founded on September 11, 2014 and is headquartered in Bowie, MD.